Skip to main content Skip to main navigation menu Skip to site footer

Successful treatment of intravenous immunoglobulin for Toxic Epidermal Necrolysis (TEN) associated with COVID-19 infection and vaccination: case reports

  • Desy Wulandari ,
  • Ricky Pebriansyah ,
  • Azwin Mengindra Putera Lubis ,
  • Zahrah Hikmah ,
  • Anang Endaryanto ,
  • pdf  |
  • Published: 2022-08-22


Abstract

Background: Toxic Epidermal Necrolysis (TEN) are rare but potentially life-threatening disorder. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of COVID-19 disease with various clinical manifestations. Two cases of TEN were reported in pediatric patients. The causal relationship between COVID-19 infection and vaccination against TEN has not been fully understood.

Case presentation: This study reports a case of a child with COVID-19 who was admitted to a pediatric hospital ward with TEN which occupies > 30% of total body surface area, and one case that suffered from TEN due to COVID-19 vaccination. All patients received IVIG 0.5 g / kg / day for 3 consecutive days.

Conclusion: The child was treated with intravenous immunoglobulin with a good outcome and clinical improvement.

Keywords: COVID-19 intravenous immunoglobulin pediatrics toxic epidermal necrolysis

References

  1. Panahi L, Amiri M, Pouy S. Clinical Characteristics of COVID-19 Infection in Newborns and Pediatrics: A Systematic Review. Arch Acad Emerg Med. 2020;8(1):e50. Published 2020 Apr 18.
  2. Perna A, Passiatore M, Massaro A, et al. Skin manifestations in COVID-19 patients, state of the art. A systematic review. Int J Dermatol. 2021;60(5):547-553. doi:10.1111/ijd.15414.
  3. Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol. 2018;35(2):182-187. doi:10.1111/pde.13383.
  4. Shi T, Chen H, Huang L, et al. Fatal pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: Three case reports. Medicine (Baltimore). 2020;99(12):e19431. doi:10.1097/MD.0000000000019431.
  5. Farajzadeh S, Ahramiyanpour N. Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID-19 outbreak?. Clin Case Rep. 2021;9(5):e04249. Published 2021 May 15. doi:10.1002/ccr3.4249.
  6. Chen Y, Xie J, Wu W, et al. Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study. Front Immunol. 2022;12:738532. Published 2022 Jan 27. doi:10.3389/fimmu.2021.738532.
  7. Xiang HR, Cheng X, Li Y, Luo WW, Zhang QZ, Peng WX. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis. Int Immunopharmacol. 2021;96:107732. doi:10.1016/j.intimp.2021.107732.
  8. Larenas-Linnemann D, Luna-Pech J, Navarrete-Rodríguez EM, et al. Cutaneous Manifestations Related to COVID-19 Immune Dysregulation in the Pediatric Age Group. Current Allergy and Asthma Reports. 2021;21(2):13. DOI: 10.1007/s11882-020-00986-6.
  9. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56(2):181-200. doi:10.1016/j.jaad.2006.04.048.
  10. Rossi CM, Beretta FN, Traverso G, Mancarella S, Zenoni D. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?. Clin Mol Allergy. 2020;18:19. Published 2020 Oct 6. doi:10.1186/s12948-020-00133-6.
  11. Saha M, D'Cruz A, Paul N, et al. Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with intravenous immunoglobulin: 'Killing 2 birds with one stone'. J Eur Acad Dermatol Venereol. 2021;35(2):e97-e98. doi:10.1111/jdv.16887.
  12. Chatproedprai S, Wutticharoenwong V, Tempark T, Wananukul S. Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital. Dermatol Res Pract. 2018;2018:3061084. Published 2018 May 7. doi:10.1155/2018/3061084.
  13. Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med. 2011;39(6):1521-1532. doi:10.1097/CCM.0b013e31821201ed.
  14. Hu CH, Chang NJ, Liu EK, Chuang SS, Chung WH, Yang JY. SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population. J Eur Acad Dermatol Venereol. 2013;27(5):628-633. doi:10.1111/j.1468-3083.2012.04502.x.
  15. Liotti L, Caimmi S, Bottau P, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90(3-S):52-60. Published 2019 Jan 29. doi:10.23750/abm.v90i3-S.8165.
  16. Kinoshita Y, Saeki H. A Review of the Pathogenesis of Toxic Epidermal Necrolysis. J Nippon Med Sch. 2016;83(6):216-222. doi:10.1272/jnms.83.216.
  17. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi:10.1016/j.jpha.2020.03.001.
  18. Parlakay AO, Ozcan S, Karaatmaca B, Tiftik M, Cinel G, Senel E. COVID-19 presenting like Steven Johnson Syndrome in a pediatric patient. N Engl J Med. 2020;382:1663–5. DOI: 10.22541/au.159286119.92728253.
  19. Mansouri P, Chalangari R, Martits-Chalangari K, Mozafari N. Stevens-Johnson Syndrome due to COVID-19 vaccination. Clin Case Rep. 2021;9(11):e05099. Published 2021 Nov 16. doi:10.1002/ccr3.5099.
  20. Stone CA Jr, Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019;85(12):2694-2706. doi:10.1111/bcp.14112.
  21. Alzughayyar TZ, Hamad WNI, Abuqweider EAS, et al. IVIG and under Burn Unit Care Yield Favorable Outcomes in Pediatric Patients with Toxic Epidermal Necrolysis: A Case Report and Literature Review. Case Rep Dermatol Med. 2020;2020:6274053. Published 2020 Jan 30. doi:10.1155/2020/6274053.
  22. Krajewski A, Mazurek MJ, Mlynska-Krajewska E, Piorun K, Knakiewicz M, Markowska M. Toxic Epidermal Necrolysis Therapy with TPE and IVIG-10 Years of Experience of the Burns Treatment Center. J Burn Care Res. 2019;40(5):652-657. doi:10.1093/jbcr/irz073.
  23. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39(7):2085-2094. doi:10.1007/s10067-020-05190-5.
  24. Larenas-Linnemann D, Luna-Pech J, Navarrete-Rodríguez EM, et al. Cutaneous Manifestations Related to COVID-19 Immune Dysregulation in the Pediatric Age Group. Curr Allergy Asthma Rep. 2021;21(2):13. Published 2021 Feb 25. doi:10.1007/s11882-020-00986-6.

How to Cite

Desy Wulandari, Ricky Pebriansyah, Azwin Mengindra Putera Lubis, Zahrah Hikmah, & Anang Endaryanto. (2022). Successful treatment of intravenous immunoglobulin for Toxic Epidermal Necrolysis (TEN) associated with COVID-19 infection and vaccination: case reports. Bali Medical Journal, 11(2), 957–961. Retrieved from https://balimedicaljournal.org/index.php/bmj/article/view/3665
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
3

Total
2

Share

Search Panel

Desy Wulandari
Google Scholar
Pubmed
BMJ Journal

Ricky Pebriansyah
Google Scholar
Pubmed
BMJ Journal

Azwin Mengindra Putera Lubis
Google Scholar
Pubmed
BMJ Journal

Zahrah Hikmah
Google Scholar
Pubmed
BMJ Journal

Anang Endaryanto
Google Scholar
Pubmed
BMJ Journal